8-K filed August 16, 2024, 7:59 PM ET ticker CTOR CIK 0001851484

M&A confidence high sentiment positive materiality 0.90

Citius Oncology completes de-SPAC business combination; CTOR begins trading

CITIUS ONCOLOGY, INC.

Citius Pharma received 65.6M shares (~92.6% ownership); 4.3M SPAC shares redeemed for ~$49.3M ($11.47 each).
Company Common Stock began trading on Nasdaq Capital Market as 'CTOR' on August 13, 2024.
Leonard Mazur appointed CEO & Chair; Jaime Bartushak CFO; Myron Holubiak Secretary/Treasurer; Myron Czuczman CMO.
Citius Pharma contributed $10M capital; waivers include LYMPHIR trademark transfer within 60 days post-closing.
71.3M shares outstanding post-closing; board of 8 directors with staggered terms; controlled company under Nasdaq rules.

item 1.01 item 2.01 item 5.06 item 9.01 item 5.02 item 3.02 item 3.03 item 4.01 item 5.01 item 5.03

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Cathy Jiang

Director

CTOR · CITIUS ONCOLOGY, INC.

Effective: 2024-08-12
Filed: August 16, 2024, 7:59 PM ET

each of Cathy Jiang and Brian Hartzband resigned as directors

Departed

Brian Hartzband

Director

CTOR · CITIUS ONCOLOGY, INC.

Effective: 2024-08-12
Filed: August 16, 2024, 7:59 PM ET

each of Cathy Jiang and Brian Hartzband resigned as directors

Departed

Xiaofeng Yuan

Chief Executive Officer

CTOR · CITIUS ONCOLOGY, INC.

Effective: 2024-08-12
Filed: August 16, 2024, 7:59 PM ET

Xiaofeng Yuan resigned as Chief Executive Officer and Chairman of the Board

Departed

Taylor Zhang

Chief Financial Officer

CTOR · CITIUS ONCOLOGY, INC.

Effective: 2024-08-12
Filed: August 16, 2024, 7:59 PM ET

Taylor Zhang resigned as Chief Financial Officer and a director

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Cathy Jiang resigned as Director at CITIUS ONCOLOGY, INC..

Action: resigned
Role: Director

Exact text from the filing

each of Cathy Jiang and Brian Hartzband resigned as directors

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Brian Hartzband resigned as Director at CITIUS ONCOLOGY, INC..

Action: resigned
Role: Director

Exact text from the filing

each of Cathy Jiang and Brian Hartzband resigned as directors

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Xiaofeng Yuan resigned as Chief Executive Officer at CITIUS ONCOLOGY, INC..

Action: resigned
Role: Chief Executive Officer

Exact text from the filing

Xiaofeng Yuan resigned as Chief Executive Officer and Chairman of the Board

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Taylor Zhang resigned as Chief Financial Officer at CITIUS ONCOLOGY, INC..

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

Taylor Zhang resigned as Chief Financial Officer and a director

View on SEC.gov

CITIUS ONCOLOGY, INC. filing history →

Source: SEC EDGAR

accession 0001213900-24-070335

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.